GoAI
Get started
Hospital Corporation of China Limited logo

Hospital Corporation of China Limited

3869.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$3.40

HK$0.00 · 0.00%

Aug 4, 9:54 AM HKT

3869.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Hospital Corporation of China Limited, an investment holding enterprise, primarily focuses on the administration and direct management of hospitals across the People's Republic of China. The company extends specialized management and consulting services to institutions like Yangsi Hospital, Cixi Hospital, and Jinhua Hospital, alongside providing comprehensive general medical care. Additionally, the firm is active in the wholesale distribution of pharmaceutical products. Established in 2014, Hospital Corporation of China Limited maintains its corporate headquarters in Beijing, PRC, and functions as a subsidiary of Vanguard Glory Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Xiaofeng Lang
Listed since
Mar 17, 2017
Employees
1,809

Market position

52-week range

Current HK$3.40

Open
HK$3.40
Previous close
HK$3.40
Volume
200
4.88× average
Average volume
41
Average daily volume
Market cap
464.09M HKD
Beta
-0.31
Market reference 1
50-day average
HK$3.402
-0.06% below average
200-day average
HK$4.3963
-22.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.44B CNY
P/E (TTM)
2.94×
P/B (TTM)
0.79×
P/S (TTM)
0.27×
EV / EBITDA
13.93×
Earnings yield
6.66%
Free cash flow yield
6.71%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
18.19%
Operating margin
8.24%
Net margin
9.27%
Return on equity
27.14%
Return on assets
5.29%
Return on invested capital
4.58%

Financial health

Debt / equity
2.1×
Current ratio
1.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends54%4%-46%-96%Gross margin, FY2021: 41.17%Gross margin, FY2022: 13.20%Gross margin, FY2023: 16.77%Gross margin, FY2024: 19.12%Gross margin, FY2025: 18.19%Operating margin, FY2021: -83.62%Operating margin, FY2022: -47.07%Operating margin, FY2023: 15.02%Operating margin, FY2024: 12.61%Operating margin, FY2025: 8.24%Net margin, FY2021: -53.95%Net margin, FY2022: -42.08%Net margin, FY2023: 9.20%Net margin, FY2024: -2.68%Net margin, FY2025: 9.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.17%. Gross margin FY2022 13.20%. Gross margin FY2023 16.77%. Gross margin FY2024 19.12%. Gross margin FY2025 18.19%. Operating margin FY2021 -83.62%. Operating margin FY2022 -47.07%. Operating margin FY2023 15.02%. Operating margin FY2024 12.61%. Operating margin FY2025 8.24%. Net margin FY2021 -53.95%. Net margin FY2022 -42.08%. Net margin FY2023 9.20%. Net margin FY2024 -2.68%. Net margin FY2025 9.27%.

Income trends

Revenue

1.47B CNY+1.99%

Operating income

121.27M CNY-33.32%

Net income

136.42M CNY+175.05M CNY
Income trends across reported periods1.67B CNY868.31M CNY64.71M CNY−738.89M CNYRevenue, FY2021: 520.29M CNYRevenue, FY2022: 1.14B CNYRevenue, FY2023: 1.43B CNYRevenue, FY2024: 1.44B CNYRevenue, FY2025: 1.47B CNYOperating income, FY2021: −435.07M CNYOperating income, FY2022: −537.99M CNYOperating income, FY2023: 214.5M CNYOperating income, FY2024: 181.86M CNYOperating income, FY2025: 121.27M CNYNet income, FY2021: −280.71M CNYNet income, FY2022: −480.95M CNYNet income, FY2023: 131.38M CNYNet income, FY2024: −38.63M CNYNet income, FY2025: 136.42M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 520.29M CNY. Revenue FY2022 1.14B CNY. Revenue FY2023 1.43B CNY. Revenue FY2024 1.44B CNY. Revenue FY2025 1.47B CNY. Operating income FY2021 −435.07M CNY. Operating income FY2022 −537.99M CNY. Operating income FY2023 214.5M CNY. Operating income FY2024 181.86M CNY. Operating income FY2025 121.27M CNY. Net income FY2021 −280.71M CNY. Net income FY2022 −480.95M CNY. Net income FY2023 131.38M CNY. Net income FY2024 −38.63M CNY. Net income FY2025 136.42M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue1.47B CNY1.44B CNY1.43B CNY1.14B CNY520.29M CNY
Cost of goods sold1.2B CNY1.17B CNY1.19B CNY992.07M CNY306.06M CNY
Gross profit267.62M CNY275.82M CNY239.36M CNY150.88M CNY214.23M CNY
Selling, general, and administrative121.17M CNY109.12M CNY130.8M CNY95.5M CNY97.88M CNY
Operating expenses146.35M CNY93.96M CNY24.86M CNY89.56M CNY649.3M CNY
Interest income63.63M CNY10.53M CNY9.74M CNY8.99M CNY6.73M CNY
Interest expense—2.58M CNY2.46M CNY4.91M CNY6.09M CNY
Depreciation and amortization54.34M CNY56.24M CNY62.86M CNY63.28M CNY41.15M CNY
Operating income121.27M CNY181.86M CNY214.5M CNY−537.99M CNY−435.07M CNY
Net income136.42M CNY−38.63M CNY131.38M CNY−480.95M CNY−280.71M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
1.23

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates1.62-0.26-2.14-4.02Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q2 '25
Q3 2022, reported Aug 30, 2022: actual -3.63, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 27, 2023: actual -0.456, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 0.995, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 0.042, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual -0.15, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual -0.155, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 20, 2025: actual 1.23, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates845.48M763.89M682.3M600.71MQ3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q2 '25
Q3 2022, reported Aug 30, 2022: actual 633.23M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 27, 2023: actual 685.66M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 776.28M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 785.72M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 772.67M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 768.9M HKD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 20, 2025: actual 812.96M HKD, estimate —, surprise —, Comparison unavailable.

3869.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 3869.HK

research.disclaimer